Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?

WEI-WU CHENCHING-HUNG LINCHIUN-SHENG HUANG2020-03-232020-03-2320162218-676Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84996866550&doi=10.21037%2ftcr.2016.10.17&partnerID=40&md5=54b283fba59e78f712f294aa1541a35bhttps://scholars.lib.ntu.edu.tw/handle/123456789/477735[SDGs]SDG3epidermal growth factor receptor 2; pertuzumab; trastuzumab; adjuvant therapy; breast cancer; cancer adjuvant therapy; cancer combination chemotherapy; cancer patient; cancer survival; drug use; human; long term survival; neoadjuvant therapy; Note; treatment responseShould pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?note10.21037/tcr.2016.10.172-s2.0-84996866550